CEO Interview: Novartis' Dan Vasella
Executive SummaryNovartis has done better than most Pharmas over the past five years, though shareholders are still dissatisfied. But CEO Dan Vasella continues playing for the long-term -- pursuing R&D innovation and cost-effective dealmaking, all within a relatively conservative strategic framework.
You may also be interested in...
Indication for non-transfusion dependent thalassemia, a cluster of inherited blood disorders that cause mild anemia, will be reviewed by FDA’s Oncologic Drugs Advisory Committee Nov. 8.